, Department of pharmacy
, Montréal, QC, Canada 4. Division of Microbiology and Infectious Diseases
American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy, Gastroenterology, vol.148, issue.1, pp.221-244, 2015. ,
Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions, Gastroenterology, vol.152, issue.6, pp.1297-309, 2017. ,
,
, Hepatitis B Virus Screening for Patients With Cancer Before Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update, J Clin Oncol, 2015.
FDA Drug Safety Communication: Boxed Warning and new recommendations to decrease risk of hepatitis B reactivation with the immunesuppressing and anti-cancer drugs Arzerra (ofatumumab) and Rituxan (rituximab). FDA [Internet, 2019. ,
Effects of rituximab dose on hepatitis B reactivation in patients with resolved infection undergoing immunologic incompatible kidney transplantation, Sci Rep, vol.8, issue.1, pp.1-8, 2018. ,
Poor recognition of risk factors for hepatitis B by physicians prescribing immunosuppressive therapy: a call for universal rather than risk-based screening, PloS One, vol.10, issue.4, p.120749, 2015. ,
Prevalence of Hepatitis B Virus, Hepatitis C Virus, and HIV Infection Among Patients With Newly Diagnosed Cancer From Academic and Community Oncology Practices, JAMA Oncol ,
, Apr, vol.1, issue.4, pp.497-505
Low Rates of Hepatitis B Virus Screening at the Onset of Chemotherapy, J Oncol Pract, 2012. ,
Trends in hepatitis B virus screening at the onset of chemotherapy in a large US cancer center, BMC Cancer, vol.13, p.534, 2009. ,
Hepatitis B virus reactivation in patients with solid tumors receiving systemic anticancer treatment, Ann Oncol Off J Eur Soc Med Oncol, vol.27, issue.12, pp.2172-84, 2016. ,
, S1 -Hepatitis B screening before treatment with rituximab
, Rossy Cancer Network, 2019.
American Gastroenterological Association Institute Guideline on the Prevention and Treatment of Hepatitis B Virus Reactivation During Immunosuppressive Drug Therapy ,
, Gastroenterology, vol.148, issue.1, pp.215-224, 2015.
Hepatitis B Virus Reactivation and Prophylaxis During Solid Tumor Chemotherapy: A Systematic Review and Meta-analysis, Ann Intern Med, vol.164, issue.1, pp.30-40, 2016. ,
Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy, Gastroenterology, vol.125, issue.6, pp.1742-1751, 2003. ,
A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization ,
, Hepatology, vol.43, issue.2, pp.233-273, 2006.
A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non ,
, Hodgkin's lymphoma: a randomized trial, Hepatol Baltim Md, vol.47, issue.3, pp.844-53, 2008.
Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B, J Clin Oncol Off J Am Soc Clin Oncol, vol.31, issue.22, pp.2765-72, 2013. ,
Systematic review with network meta-analysis: Comparative efficacy of oral nucleos(t)ide analogues for the prevention of chemotherapy-induced hepatitis B virus reactivation, Oncotarget ,
Meta-analysis of prophylactic entecavir or lamivudine against hepatitis B virus reactivation, Ann Hepatol, vol.15, issue.4, pp.501-512, 2016. ,
Comparison of entecavir and lamivudine in preventing HBV reactivation in lymphoma patients undergoing chemotherapy: a meta-analysis, Int J Clin Pharm, vol.38, issue.5, pp.1035-1078, 2016. ,
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance, Hepatol Baltim Md, vol.67, issue.4, pp.1560-99, 2018. ,
, European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection, J Hepatol, vol.57, issue.1, pp.167-85, 2012.
Recommendations for identification and public health management of persons with chronic hepatitis B virus infection, MMWR Recomm Rep Morb Mortal Wkly Rep Recomm Rep, vol.57, issue.8, pp.1-20, 2008. ,
Hepatitis B Virus Screening Before Chemotherapy for Lymphoma: A Cost-Effectiveness Analysis, J Clin Oncol, vol.30, issue.26, pp.3167-73, 2012. ,
Cost-Effectiveness of Universal Hepatitis B Virus Screening in Patients Beginning Chemotherapy for Solid Tumors, J Clin Oncol, vol.29, issue.24, pp.3270-3277, 2011. ,
Introduction of routine hepatitis B screening for all patients receiving cancer treatment, Neth J Med, 2019. ,
Screening for hepatitis B virus prior to chemotherapy: A quality improvement project, J Clin Oncol, vol.31, pp.158-158, 2013. ,
,
Successful implementation of a universal screening program to prevent hepatitis B reactivation in a large cancer center ,
, Hepatology, vol.58, issue.S1, p.848, 2013.
, Hepatitis B -Chapter 4 -2020 Yellow Book | Travelers' Health | CDC, 2019.
Defining and grading HBV reactivation: Defining and Grading HBV Reactivation. Clin Liver Dis, vol.5, pp.35-43, 2015. ,
Outcomes of the implementation of the computer-assisted HBView system for the prevention of hepatitis B virus reactivation in chemotherapy patients: a retrospective analysis, J Pharm BIBLIOGRAPHIE ,
, World Health Organization, World Health Organization, Department of HIV/AIDS. Guidance on prevention of viral hepatitis B and C among people who inject drugs, 2012.
,
, , 2019.
,
,
, 2020 Yellow Book | Travelers' Health | CDC, 2019.
,
A snapshot of virological presentation and outcome of immunosuppression-driven HBV reactivation from real clinical practice: Evidence of a relevant risk of death and evolution from silent to chronic infection, J Viral Hepat. juill, vol.26, issue.7, pp.846-55, 2019. ,
Recommendations for identification and public health management of persons with chronic hepatitis B virus infection, MMWR Recomm Rep Morb Mortal Wkly Rep Recomm Rep. 19 sept, vol.57, issue.8, pp.1-20, 2008. ,
, European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection, J Hepatol. juill, vol.57, issue.1, pp.167-85, 2012.
Hepatitis B virus-induced oncogenesis, World J Gastroenterol WJG. 7 janv, vol.13, issue.1, p.74, 2007. ,
New perspectives on the hepatitis B virus life cycle in the human liver, J Clin Invest, vol.126, issue.3, pp.833-839 ,
Diagnosis of hepatitis B, Ann Transl Med, vol.4, issue.18, p.338, 2016. ,
Les génotypes du virus de l'hépatite B, Gastroenterol Clin Biol, vol.26, pp.1005-1012, 2002. ,
Clinical practice : prevention of Hepatitis B with the Hepatitis B Vaccine, N Engl J Med, vol.351, issue.27, pp.2832-2840, 2004. ,
Vaccination prophylactique contre l'hépatite B : actualité et avenir, Gastroenterol Clin Biol, vol.23, issue.4, p.453, 1999. ,
Résumé des Caractéristiques du Produit : Engerix B [en ligne, 2016. ,
, European Comission. Résumé des Caractéristiques du Produit : HBVAXPRO
Vaccin contre l'hépatite B : Guide canadien d'immunisation [en ligne, 2007. ,
Calendrier des vaccinations et recommandations vaccinales, 2019. ,
, , 2019.
Update on Diagnosis, Management, and Prevention of Hepatitis B Virus Infection, Clin Microbiol Rev. avr, vol.12, issue.2, pp.351-66, 1999. ,
for the High Value Care Task Force of the American College of Physicians and the Centers for Disease Control and Prevention. Hepatitis B Vaccination, Screening, and Linkage to Care: Best Practice Advice From the American College of Physicians and the Centers for Disease Control and Prevention, Ann Intern Med. 5 déc, vol.167, issue.11, p.794, 2017. ,
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance, Hepatol Baltim Md, vol.67, issue.4, pp.1560-99, 2018. ,
, Hepatitis B (Chronic): Diagnosis and Management of Chronic Hepatitis B in Children, Young People and Adults
National Institute for Health and Care Excellence (UK), 2013. ,
,
Chronic hepatitis B: update 2009, Hepatol Baltim Md. sept, vol.50, issue.3, pp.661-663, 2009. ,
Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus, Antiviral Res. 1 janv, vol.125, pp.63-70, 2016. ,
Defining and grading HBV reactivation: Defining and Grading HBV Reactivation, Clin Liver Dis. févr, vol.5, issue.2, pp.35-43, 2015. ,
Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy ,
, Gastroenterology. janv, vol.100, issue.1, pp.182-190, 1991.
Recent US Food and Drug Administration warnings on hepatitis B reactivation with immunesuppressing and anticancer drugs: just the tip of the iceberg?, Hepatol Baltim Md. févr, vol.61, issue.2, pp.703-714, 2015. ,
Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy, Ann Intern Med. 1 avr, vol.148, issue.7, pp.519-547, 2008. ,
Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions, Gastroenterology. mai, vol.152, issue.6, pp.1297-309, 2017. ,
,
, Hepatitis B Virus Screening for Patients With Cancer Before Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update, J Clin Oncol. juill, vol.33, pp.2212-2232, 2015.
FDA Drug Safety Communication: Boxed Warning and new recommendations to decrease risk of hepatitis B reactivation with the immunesuppressing and anti-cancer drugs Arzerra (ofatumumab) and Rituxan (rituximab) ,
,
Effects of rituximab dose on hepatitis B reactivation in patients with resolved infection undergoing immunologic incompatible kidney transplantation. Sci Rep, vol.8, pp.1-8, 2018. ,
Trends in hepatitis B virus screening at the onset of chemotherapy in a large US cancer center, BMC Cancer, vol.13, p.534, 2013. ,
Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: A prospective study, J Med Virol. 1 août, vol.70, issue.4, pp.553-61, 2003. ,
The management of chronic hepatitis B in the immunocompromised patient: Recommendations from a single topic meeting, J Clin Virol. 1 avr, vol.41, issue.4, pp.243-54, 2008. ,
Hepatitus B virus reactivation in HBV-DNA negative and positive patients with hematological malignancies, Hematology. 1 août, vol.15, issue.4, pp.240-244, 2010. ,
Chronic hepatitis B, non-Hodgkin's lymphoma, and effect of prophylactic antiviral therapy, J Clin Virol. 1 août, vol.51, issue.4, pp.241-246, 2011. ,
Risk of hepatitis B reactivation and the role of novel agents and stem-cell transplantation in multiple myeloma patients with hepatitis B virus (HBV) infection, Ann Oncol. 1 févr, vol.23, issue.2, pp.421-427, 2012. ,
Non-Hodgkin's Lymphomas ,
, JNCCN J Natl Compr Cancer Netw. 1 déc, vol.10, issue.12, pp.1487-98, 2012.
Evaluation and management of hepatitis B virus infection in hematopoietic stem cell transplantation: before and after transplantation, Expert Rev Anti Infect Ther. 1 août, vol.9, issue.8, pp.641-52, 2011. ,
Hepatitis B Virus Reactivation in Lymphoma Patients With Prior Resolved Hepatitis B Undergoing Anticancer Therapy With or Without Rituximab, J Clin Oncol. 15 déc, vol.27, issue.4, pp.605-616, 2008. ,
Hepatitis B virus reactivation with a rituximab-containing regimen, World J Hepatol, vol.7, issue.21, p.2344, 2015. ,
Hepatitis B screening, prophylaxis and re-activation in the era of rituximab-based chemotherapy ,
, Liver Int, vol.31, issue.3, pp.330-339, 2011.
,
, Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports, Ann Oncol. 1 mai, vol.22, issue.5, pp.1170-80, 2011.
An Argument for the Universal Prophylaxis of Hepatitis B Infection in Patients Receiving Rituximab: A 7-Year Institutional Experience of Hepatitis Screening, The oncologist. 1 avr, vol.16, pp.579-84, 2011. ,
Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma, Hepatology, vol.37, issue.6, pp.1320-1328, 2003. ,
Hepatitis B virus DNA contains a glucocorticoid-responsive element, Proc Natl Acad Sci, vol.83, issue.6, p.1627, 1986. ,
Hepatitis B virus reactivation and alemtuzumab therapy, Eur J Haematol, vol.74, issue.3, pp.254-262, 2005. ,
Fulminant hepatitis B and acute hepatitis B due to intrafamilial transmission of HBV after chemotherapy for non-Hodgkin's lymphoma in an HBV carrier, Eur J Pediatr. 24 mai, vol.169, issue.2, p.167, 2009. ,
Hepatitis B reactivation despite entecavir prophylaxis in a patient with chronic lymphocytic leukaemia receiving bendamustine, J Antimicrob Chemother, vol.67, issue.2, pp.510-511, 2012. ,
Reactivation of hepatitis B virus following bendamustine-containing chemotherapy in a patient with multiple myeloma, Leuk Lymphoma. 1 mai, vol.52, issue.5, pp.916-924, 2011. ,
Fatal hepatitis B virus reactivation in a chronic myeloid leukemia patient during imatinib mesylate treatment, Leuk Lymphoma. 1 janv, vol.47, issue.1, pp.155-162, 2006. ,
Doxorubicin Activates Hepatitis B Virus (HBV) Replication in HBV-harboring Hepatoblastoma Cells. A Possible Novel Mechanism of HBV Reactivation in HBV Carriers Receiving Systemic Chemotherapy, ANTICANCER Res, vol.6, 2004. ,
A long-term follow-up study on hepatitis B surface antigen-positive patients undergoing allogeneic hematopoietic stem cell transplantation, Blood. 15 juill, vol.106, issue.2, pp.464-473, 2005. ,
Hepatitis B Virus Reactivation following Allogeneic Hematopoietic Stem Cell Transplantation, Biol Blood Marrow Transplant. 1 sept, vol.15, issue.9, pp.1049-59, 2009. ,
Prophylactic use of lamivudine for hepatitis B exacerbation in post-operative breast cancer patients receiving anthracycline-based adjuvant chemotherapy, Br J Cancer. févr, vol.104, issue.4, pp.559-63, 2011. ,
High hepatitis B virus (HBV) DNA viral load is an important risk factor for HBV reactivation in breast cancer patients undergoing cytotoxic chemotherapy, J Viral Hepat, vol.11, issue.1, pp.55-64, 2004. ,
Hepatitis B reactivation after chemotherapy: two decades of clinical research ,
, Hepatol Int. juin, vol.2, issue.2, pp.152-62, 2008.
Clinical and virological factors associated with hepatitis B virus reactivation in HBsAg-negative and anti-HBc antibodies-positive patients undergoing chemotherapy and/or autologous stem cell transplantation for cancer, J Viral Hepat, vol.17, issue.11, pp.807-822, 2010. ,
American Gastroenterological Association Institute Guideline on the Prevention and Treatment of Hepatitis B Virus Reactivation During Immunosuppressive Drug Therapy ,
, Gastroenterology. janv, vol.148, issue.1, pp.215-224, 2015.
American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases, J Clin Oncol Off J Am Soc Clin Oncol. 1 juill, vol.28, pp.3199-202, 2010. ,
Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy, Br J Cancer, vol.90, issue.7, pp.1306-1311, 2004. ,
High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation, Blood. 1 avr, vol.99, issue.7, pp.2324-2354, 2002. ,
A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial, Hepatol Baltim Md. mars, vol.47, issue.3, pp.844-53, 2008. ,
Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy, Gastroenterology. déc, vol.125, issue.6, pp.1742-1751, 2003. ,
Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma: a meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance, Haematologica. juill, vol.94, issue.7, pp.998-1005, 2009. ,
Hepatitis B prophylaxis in patients undergoing chemotherapy for lymphoma: A decision analysis model, Hepatology, vol.46, issue.4, pp.1049-56, 2007. ,
A review of the one-year incidence of resistance to lamivudine in the treatment of chronic hepatitis B : Lamivudine resistance ,
, Hepatol Int. 1 janv, vol.2, pp.440-56, 2009.
Entecavir Therapy for up to 96 Weeks in Patients With HBeAg-Positive Chronic Hepatitis B ,
, Gastroenterology, vol.133, issue.5, pp.1437-1481, 2007.
Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B, N Engl J Med. 9 mars, vol.354, issue.10, pp.1011-1031, 2006. ,
Comparison of entecavir and lamivudine in preventing hepatitis B reactivation in lymphoma patients during chemotherapy, J Viral Hepat. déc, vol.18, issue.12, pp.877-83, 2011. ,
Prospective study of hepatitis b virus reactivation in hbsag-negative patients after chemotherapy with rituximab: hbv-dna monitoring and entecavir prophylaxis, J Hepatol. 1 avr, vol.56, p.206, 2012. ,
Comparison of entecavir and lamivudine in preventing HBV reactivation in lymphoma patients undergoing chemotherapy: a meta-analysis, Int J Clin Pharm, vol.38, issue.5, pp.1035-1078, 2016. ,
Entecavir versus lamivudine for hepatitis B prophylaxis in patients with haematological disease, Liver Int Off J Int Assoc Study Liver. sept, vol.33, issue.8, pp.1203-1213, 2013. ,
Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial, JAMA. 17 déc, vol.312, issue.23, pp.2521-2551, 2014. ,
Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B, J Clin Oncol Off J Am Soc Clin Oncol. 1 août, vol.31, issue.22, pp.2765-72, 2013. ,
Hepatitis B virus management to prevent reactivation after chemotherapy: a review. Support Care Cancer Off J Multinatl Assoc Support Care Cancer, vol.20, pp.2999-3008, 2012. ,
Prevention and Treatment of Cancer-Related Infections, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology, J Natl Compr Cancer Netw JNCCN, vol.14, issue.7, pp.882-913, 2016. ,
, Institute of Medicine (US) Committee on the Prevention and Control of Viral Hepatitis Infection. Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C
,
Hepatitis B Virus Screening Before Chemotherapy for Lymphoma: A Cost-Effectiveness Analysis, J Clin Oncol, vol.30, issue.26, pp.3167-73, 2012. ,
Cost-Effectiveness Analysis of Hepatitis B Virus Screening and Management in Patients With Hematologic or Solid Malignancies Anticipating Immunosuppressive Cancer Therapy, JCO Clin Cancer Inform, vol.3, pp.1-12, 2019. ,
Cost-Effectiveness of Universal Hepatitis B Virus Screening in Patients Beginning Chemotherapy for Solid Tumors, J Clin Oncol. 25 juill, vol.29, issue.24, pp.3270-3277, 2011. ,
Screening for hepatitis B in chemotherapy patients: survey of current oncology practices, Aliment Pharmacol Ther. 15 janv, vol.31, issue.2, pp.240-246, 2010. ,
Low Rates of Hepatitis B Virus Screening at the Onset of Chemotherapy, J Oncol Pract. juill, vol.8, issue.4, pp.32-41, 2012. ,
Prevalence of Hepatitis B Virus, Hepatitis C Virus, and HIV Infection Among Patients With Newly Diagnosed Cancer From Academic and Community Oncology Practices, JAMA Oncol. 1 avr, vol.5, issue.4, pp.497-505, 2019. ,
Hepatitis B virus reactivation in patients with solid tumors receiving systemic anticancer treatment, Ann Oncol Off J Eur Soc Med Oncol, vol.27, issue.12, pp.2172-84, 2016. ,
S1-Hepatitis B screening before treatment with rituximab, 2018. ,
Why we should routinely screen Asian American adults for hepatitis B: a cross-sectional study of Asians in California. Hepatol Baltim Md, vol.46, pp.1034-1074, 2007. ,
Hepatitis B and hepatitis C prevalence and treatment referral among Asian Americans undergoing community-based hepatitis screening, Am J Public Health. 1 avr, vol.100, issue.1, pp.118-124, 2010. ,
Introduction of routine hepatitis B screening for all patients receiving cancer treatment, Neth J Med. janv, vol.77, issue.1, pp.19-24, 2019. ,
,
Successful implementation of a universal screening program to prevent hepatitis B reactivation in a large cancer center ,
, Hepatology, vol.58, issue.S1, p.848, 2013.
Outcomes of the implementation of the computer-assisted HBView system for the prevention of hepatitis B virus reactivation in chemotherapy patients: a retrospective analysis, J Pharm Health Care Sci, vol.1, p.29, 2015. ,
Screening for hepatitis B virus prior to chemotherapy: A quality improvement project, J Clin Oncol, vol.31, pp.158-158, 2013. ,
Screening for hepatitis B surface antigen before chemotherapy: current practice and opportunities for improvement, Curr Oncol, vol.17, issue.6, pp.32-40, 2010. ,
The efficacy of a computer alert programme for increasing HBV screening rates before starting immunosuppressive therapy, Acta Gastro-Enterol Belg. juin, vol.82, issue.2, pp.279-84, 2019. ,
Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Algorithme décisionnel du CHUM sur le dépistage, vol.26, pp.116-141, 2015. ,